Patents by Inventor David A. Proia

David A. Proia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS
    Publication number: 20140315943
    Abstract: A pharmaceutical composition comprising an mTOR/PI3K inhibitor, and an Hsp90 inhibitor according to the following formulae (I) and (Ia) or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.
    Type: Application
    Filed: May 23, 2012
    Publication date: October 23, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David Proia, Suqin He
  • COMBINATION CANCER THERAPY WITH AN HSP90 INHIBITOR AND AN ANTIMETABOLITE
    Publication number: 20140296176
    Abstract: The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (I) 40 or (Ia) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives.
    Type: Application
    Filed: August 17, 2012
    Publication date: October 2, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: David Proia, Julie Friedland
  • TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20140294808
    Abstract: Methods of treating cancer with a compound of formulae (I) or (Ia) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (Ia). Further provided are methods of treating non-small cell lung cancer with a mutation in ALK with a compound of formulae (I) or (Ia); a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein.
    Type: Application
    Filed: July 9, 2012
    Publication date: October 2, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Iman El-Hariry, David Proia, Vojo Vukovic
  • COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS
    Publication number: 20140286902
    Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 25, 2014
    Inventor: David Proia
  • CANCER THERAPY USING A COMBINATION OF HSP90 INHIBITORS WITH TOPOISOMERASE I INHIBITORS
    Publication number: 20140255348
    Abstract: A pharmaceutical combination comprising a topoisomerase I inhibitor, and an Hsp90 inhibitor according to the following formulae (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 11, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventor: David Proia
  • COMBINATION THERAPY OF HSP90 INHIBITORS WITH BRAF INHIBITORS
    Publication number: 20140256680
    Abstract: A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables are defined therein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: November 14, 2012
    Publication date: September 11, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: David Proia, Jaime Acquaviva
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MEK INHIBITORS
    Publication number: 20140228418
    Abstract: A pharmaceutical composition comprising an MEK inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia) or tautomers or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.
    Type: Application
    Filed: May 22, 2012
    Publication date: August 14, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: David Proia, Jaime Acquaviva
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS
    Publication number: 20140194388
    Abstract: A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.
    Type: Application
    Filed: May 25, 2012
    Publication date: July 10, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David Proia, Suqin He
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY
    Publication number: 20140051664
    Abstract: Methods for treating cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the following structural formula a tautomer, or a pharmaceutically acceptable salt thereof in combination with radiotherapy. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: February 22, 2012
    Publication date: February 20, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Kevin P. Foley, David Proia
  • PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20140051665
    Abstract: Method for treating a subject with prostate cancer, comprising administering to the an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 20, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David Proia, Suqin He
  • HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS
    Publication number: 20140045908
    Abstract: Methods for treating a subject with cancer mediated through dysregulated, aberrant, or defective JAK/STAT signaling, are provided, comprising determining the level of the JAK/STAT signaling in a sample derived from a subject in need of treatment, wherein the presence of dysregulated, aberrant, or defective JAK/STAT signaling is indicated, administering to the subject an effective amount of a triazolone compound as described herein.
    Type: Application
    Filed: February 24, 2012
    Publication date: February 13, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Kevin P. Foley, David Proia
  • COMBINATION BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20140005145
    Abstract: Methods for treating breast cancer, comprising administering to the subject an effective amount of a selective estrogen receptor modulator and an effective amount of a compound represented by the following structural formula: (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: December 7, 2011
    Publication date: January 2, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventor: David Proia
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS
    Publication number: 20130331357
    Abstract: A composition comprising a proteasome inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder such as cancer in a subject in need thereof, using pharmaceutical combinations described herein.
    Type: Application
    Filed: January 10, 2012
    Publication date: December 12, 2013
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David Proia, Julie Friedland
  • CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR
    Publication number: 20130171105
    Abstract: A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Application
    Filed: May 23, 2011
    Publication date: July 4, 2013
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR
    Publication number: 20130156755
    Abstract: A pharmaceutical combination comprising a VEGF inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical combinations described herein.
    Type: Application
    Filed: April 19, 2011
    Publication date: June 20, 2013
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A EGFR INHIBITOR
    Publication number: 20130150385
    Abstract: A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae (I) or (Ia) a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
    Type: Application
    Filed: April 19, 2011
    Publication date: June 13, 2013
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
  • COMBINATION CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20120245186
    Abstract: Disclosed is a method for treating a subject with cancer, comprising administering to the subject an effective amount of paclitaxel or a paclitaxel analogue and an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: October 19, 2010
    Publication date: September 27, 2012
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia